Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data

Abstract Background Safety remains a significant concern for biologic drugs, and studies are needed to ensure a comparable safety profile for biosimilars and their legacy treatments. Using Canadian administrative health data from 2015–2019, we compared the incidence of serious infection between bios...

Descripció completa

Dades bibliogràfiques

Autors principals:	Marina G. Birck, Luck Lukusa, Denis Choquette, Gilles Boire, Walter P. Maksymowych, Harminder Singh, Waqqas Afif, Sasha Bernatsky
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-09-01
Col·lecció:	BMC Rheumatology
Matèries:	Biosimilar pharmaceuticals Infections Safety Observational study
Accés en línia:	https://doi.org/10.1186/s41927-024-00415-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!